MedPath

Impact of artificial intelligence based scoring of hormone expression in breast cancer on treatment decision making.

Not yet recruiting
Conditions
Malignant neoplasm of breast of unspecified site,
Registration Number
CTRI/2021/03/031926
Lead Sponsor
Applied Materials India PVT LTD
Brief Summary

This is a prospective cross-sectional study that will be conducted on cases of breast carcinoma. Glass slides prepared from blocks containing tumour tissue would be stained by immunohistochemistry for ER, PR, and HER2/neu expressions and Ki 67. The IHC slides of ER, PR, HER2 neu and Ki 67 will be de-identified and coded. 4 pathologists will independently score ER, PR, Her 2/neu and Ki 67 expression.

The results of manual scoring will be compared with that of artificial intelligence (AI) based scoring. The scores of IHC expression of ER, PR, Her 2 and ki67 obtained manually from pathologists and AI-based algorithm will be provided to the blinded medical oncologist who will decide and chart out the treatment plan separately for both manual score and the AI-based score based on these biomarkers expression scores. The treatment plan for both arms will be compared to study the impact of the AI-based solutions on clinical decision making and planning of further treatment for a patient with breast cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
75
Inclusion Criteria

Female patients, post-surgery with diagnosed breast carcinoma subjected to immunohistochemical analysis of hormone receptors(ER, PR, Her2-neu and Ki67) on the breast specimen.

Exclusion Criteria

Cases were consent could not be obtained.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Utility and effectiveness of computer assisted artificial intelligence (AI) based analysis to objectively quantify the biomarker expression in breast cancer.4 months
Secondary Outcome Measures
NameTimeMethod
Impact of AI based scoring in deciding therapy modulation in patient diagnosed with breast cancer.4 months

Trial Locations

Locations (1)

Kasturba Hospital

🇮🇳

Udupi, KARNATAKA, India

Kasturba Hospital
🇮🇳Udupi, KARNATAKA, India
Dr Brij Mohan Kumar Singh
Principal investigator
9663984859
brij.singh@manipal.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.